Earnings from Teva Pharmaceutical Industries Limited [TEVA] are scheduled on April 28, 2021, before the market opens. It is expected that the company will report weak earnings for the quarter ending Mar 2021.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
TEVA Stock Earnings Outlook For The Current Quarter
The consensus estimates for the quarter suggest that the company would earn $0.59 per share on revenue of $4.02B. Taking a look at the future, the company is projected to report revenue of $4.04B at an earnings per share of $0.61 for the Jun 2021 quarter. The estimates represent year-over-year improvements of 0.70% in revenue and 5.31% in earnings per share for the company.
TEVA Stock Earnings Forecast For The Current Year
For the full financial year, Teva Pharmaceutical Industries Limited [NYSE:TEVA] is forecasted to generate revenue of $16.68B. The figure is about $20.0 million above what the company actually reported for the fiscal year 2020. In terms of EPS, it is estimated to be $2.61 in 2021, which is $0.04 higher than the figure in FY20. Based on current estimates, earnings are expected to grow 1.60% this year, 4.60% next year, and 5.60% annually over the next five years. With regard to sales, forecasts suggest an incline of 0.20% in current fiscal year and 0.70% over following year.
TEVA Stock Price Performance
At the close of Tuesday’s session, Teva Pharmaceutical Industries Limited [NYSE:TEVA] finished down -2.26% at $10.37. The stock’s highest single-day price was $10.43, and its lowest was $10.235. Its price rose 2.57% in the last five days. Since the beginning of the year, Teva Pharmaceutical Industries Limited’s shares are up nearly 7.46%. However, the share price is -22.03% below its one year high. The top price reached by the shares of the company was $13.30 on 02/09/21, while the 52-week low came on 01/04/21, when the shares were $9.71. In the past year, shares of the company have fallen -3.26%. At 50 days, the moving average achieved is $11.00 while at 200 days, the moving average is $10.52. There were 14.88 million shares traded in the last session, up from 6.54 million in the previous session.
Teva Pharmaceutical Industries Limited [NYSE:TEVA] Stock Valuation Metrics
Investors may find it helpful to look at historical price-sales ratios, and in the case of this stock, 0.68 PS value ratio is reported for the last one year of reported earnings. This is below the average return 3.18 for the industry, which means TEVA offers an attractive investment opportunity than its competitors do.
TEVA Share Price Support And Resistance Levels
Based on the daily chart, the immediate backing lies around the 10.37 level, and the violation of this level will cause a further drop to 10.26 level. At the upper end, 10.65 remains a key resistance. As the stock increases, it may find resistance at 10.54. In the 14-day chart, the Relative Strength Index standing at 40.93 suggests a technical neutral stance while the MACD standing at -0.18 indicates price will decrease in the next trading period. Stochastic %K at 29.45% suggests holding the stock while Percent R indicator at 71.13% suggests bearish price movement.
How much is the short interest in Teva Pharmaceutical Industries Limited?
There have been a drop in short interest in the Teva Pharmaceutical Industries Limited Financial stock, with short interest down by -6.54 million shares to 36.37 million shares on Mar 14, 2021. According to data provided by Yahoo Finance, the short interest on Apr 14, 2021 stood at 29.83 million shares. This 17.98% increase suggests some bearish sentiment was experienced by the stock.
How do analysts view Teva Pharmaceutical Industries Limited?
In regard to the share price forecast for Teva Pharmaceutical Industries Limited stock, the analysts, as surveyed by FactSet, forecast the price to reach $12.00 in the next twelve months, representing almost an 13.58% growth from its recent price of $10.37. Among Teva Pharmaceutical Industries Limited stock projections, $17.00 is the highest analyst target for the stock, while $9.00 is the lowest. Despite this, 21 analysts who share their consensus rating for TEVA in 2021 agree that the stock is a Hold.